Table 4.
Concentration (µg/mL) | Relative Total Growth | Percent Plating Efficiency | Mutant Frequency (× 10−6) | MF (S/L) a | IMF (MF-SMF) (× 10−6) | |||||
---|---|---|---|---|---|---|---|---|---|---|
Experiment 1 | Experiment 2 | Experiment 1 | Experiment 2 | Experiment 1 | Experiment 2 | Experiment 1 | Experiment 2 | Experiment 1 | Experiment 2 | |
0 | 100 | 100 | 93 | 102 | 155 | 146 | 96/59 | 82/64 | - | - |
0.04 CYN-0.4 MC | 96 | 84 | 82 | 84 | 94 | 100 | 43/51 | 42/58 | −61 | −46 |
0.08 CYN-0.8 MC | 82 | 72 | 91 | 91 | 95 | 95 | 50/45 | 50/45 | −60 | −51 |
0.16 CYN-1.6 MC | 58 | 51 | 95 | 100 | 98 | 95 | 48/50 | 49/47 | −57 | −51 |
0.33 CYN-3.3 MC | 58 | 56 | 102 | 100 | 98 | 105 | 56/43 | 60/45 | −57 | −41 |
0.67 CYN-6.7 MC | 26 | 31 | 118 | 113 | 120 | 132 | 62/58 | 77/55 | −35 | −14 |
1.35 CYN-13.5 MC | 16 | 16 | 130 | 116 | 70 | 91 | 29/41 | 38/53 | −85 | −55 |
CP (3 µg/mL) | 99 | 81 | 65 | 73 | 480 *** | 433 *** | 228/252 | 213/220 | 325 | 286 |
Positive controls: methylmethanesulfonate, MMS 10 μg/mL without S9 fraction and cyclophosphamide, CP 3 μg/mL with S9 fraction.